bnAbs for HIV treatment: Clinical Research Considerations

E-mail Print
The bnAbs for HIV treatment: Clinical Research Considerations meeting was held in Washington DC on Monday, October 30, 2023

Materials

pdfAgenda
pdfMeeting Report

Introduction

Welcome, Housekeeping, and Forum Overview
Nick Murdock, FCR
pdfIntroductory Remarks and Overall Project Goals
Veronica Miller, FCR
pdfWhere do bNAbs Fit in the Treatment Landscape?
Joe Eron, UNC

Session I: Lessons from ARVs

Measuring Antiviral Activity in ARVs
Dan Kuritzkes, Brigham & Women’s
pdfLessons from CCR5 Antagonists
Jackie Reeves, LabCorp-Monogram
Clinical vs. Statistical Cutoffs of Antiviral Activity
Moderated Discussion
Open Discussion/Q&A
All Speakers
Sean Collins, Gilead
Simon Collins, HIV i-Base
Ben Lorenz, FDA

Session II: Overview of bNAbs Development Programs

pdfN6LS
Peter Leone, ViiV
pdf3BNC-117LS
Marina Caskey, Rockefeller University
pdfIAVI-developed bNAbs
Rip Ballou, IAVI
Open Discussion/Q&A
All Speakers
Richard Jefferys, TAG
Damon Deming, FDA

Session III: Measurements of Susceptibility

pdfMeasuring in-vitro Susceptibility to bNAbs
Nicole Doria-Rose, VRC
pdfExploring Susceptibility Cutoff Definitions
Yunda Huang, HVTN
Open Discussion/Q&A
All Speakers
Julia Lathrop, FDA

Session IV: Diagnostic Approaches

Using Pro-Viral DNA vs. Plasma RNA
Moderated Discussion
pdfThe Use of Phenotypic vs. Genotypic Assays
Laurie VanderVeen, Gilead
Open Discussion/Q&A
All Speakers
Julia Lathrop, FDA